Overview

* Bioceres Q4 revenue falls 40% YoY, missing analyst expectations, per LSEG data

* Adjusted EBITDA for Q4 was negative $4.5 mln, missing estimates, per LSEG data

* Company increased net cash flow from operations by 27% YoY despite profitability decline

Outlook

* Bioceres to cut CAPEX and R&D by 50% for FY26 and FY27

* Company targets 10-12% operating expense savings

* Bioceres aims to maintain working capital at 4-5 months of sales

* Company extends convertible note maturities under new terms

Result Drivers

* ARGENTINA CHALLENGES - Weaker demand in Argentina and macroeconomic pressures significantly impacted revenue and gross profit

* SEED BUSINESS STRATEGY - Shift in seed business strategy contributed to nearly half of the gross margin decline, according to CEO Federico Trucco

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Miss $74.70 $111.70

Revenue mln mln (4

Analysts

)

Q4 Miss -$4.50 $18.40

Adjusted mln mln (2

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the agricultural chemicals peer group is "buy"

* Wall Street's median 12-month price target for Bioceres Crop Solutions Corp ( BIOX ) is $7.25, about 63.2% above its September 8 closing price of $2.67

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 27 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)